

# Vaishali Pharma Ltd.

(Formerly known as Vaishali Pharma Pvt. Ltd.)



**CORPORATE & REGISTERED OFFICE :**  
706-709, 7th Floor, Aravali Business Centre,  
R. C. Patel Road, Off. Sodawala Lane,  
Borivali (West), Mumbai-400 092.  
Tel.: +91-22-4217 1819 (30 Lines)  
Fax: +91-22-2892 8833  
E-mail : [info@vaishalipharma.com](mailto:info@vaishalipharma.com)  
[export@vaishalipharma.com](mailto:export@vaishalipharma.com)  
**CIN - L52310MH2008PLC181632**

29<sup>th</sup> April, 2020

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1,  
G Block, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051

**Stock Code: VAISHALI**

Dear Sir/Madam,

**Sub: Press Release on launch of Personal Care and Hygiene Products to protect against COVID-19.**

We refer to captioned subject and wish to inform that the Company has launched personal care and hygiene products, such as sanitizers, PPE, face shields and face masks.

Please find enclosed herewith a copy of Press Release giving information about the same.

We request you to kindly take the same on record.

Thanking you.

Yours faithfully,  
**For Vaishali Pharma Limited**

Sd/-  
Atul Arvind Vasani  
**Managing Director**

April 29 2020

To  
The Corporate Relationship Manager,  
NSE, BKC.  
Mumbai,

Reference: Launch of Personal Care and Hygiene Products to protect against COVID-19

Vaishali Pharma ('The Company') has taken a stride forward to fight against the COVID-19 pandemic by launching personal care and hygiene products, such as sanitizers, PPE, face shields and face masks. The launch of these products show the capability and adaptability of the Company in catering to the needs of the consumers and markets. We are expecting a lot of demand for medicines & consumables from all countries worldwide including India amidst this pandemic. We hope to provide people with good quality and value-for-money products in the Indian Market as well the global market. We are providing our products to corporates, hospitals and retails stores in all SKUs required. We hope to have our first appearance in the Indian market with some differentiation in such products. The sanitizer we launched is Herbal based with natural extracts in oil base giving hands smooth effect even after using it frequently.

We have received a lot of enquiries for export of the same and we are hopeful that we will be able to fulfill their requirements once the ban on exports of these items is lifted. Indian Pharmaceutical products have received greater acceptance across global markets especially during such precarious times. Governments across the World have appreciated the help of the Indian Government in terms of extending supply of the most sought after drug – Hydroxychloroquine, which seems to be helpful in the fight against the COVID-19. The Company is all geared to supply Hydroxychloroquine to its customers once it gets the necessary clearance from the Government. The supply is also intended to meet the policy of meeting Social Obligations of the Company towards the wellbeing of society and its customers.

Commenting on the launch of these products, Mr. Atul Vasani, Managing Director, Vaishali Pharma said "In our constant endeavour to cater to the Healthcare needs of our Society, Vaishali Pharma has followed a dynamic approach to its business. Considering the current situation, the Company has taken efforts to provide basic hygienic and protective products to fight the COVID-19. Our team's efforts and the support of our trusted partners ensured that we launch these products in a short span of time right from conception, development and manufacturing. We

will keep striving in innovating new products to meet the needs of domestic and international markets”

#### **About Vaishali Pharma Limited:**

Vaishali Pharma Limited (NSE: VAISHALI), abided by the norms of extending uncompromised quality products, has raised the standards of the Pharmaceutical & Healthcare industry time and again. Through unwavering dedication, consistent efforts and endless innovation we enjoy an Export House status. The Company’s product quality is certified by ISO 9001:2015 certification for the Quality Management from ISC Global.

Incorporated in the year 1989, Vaishali Pharma Limited is a globally well trusted brand with high quality products, accepted by companies across the globe. The Company is amongst the leading players in the supply of pharma products – Bulk Drugs / APIs, Formulations, Surgical Products, Veterinary supplements, Herbal & Nutraceutical products, with a well-established brand known for its high-quality products & services amongst various clients globally. The Company has over 80 formulation brands marketed in multiple countries; of which dossier is in CTD format along with its respective bioequivalence. The Company has built a robust pipeline of around 250 Dossiers (with around 120 approvals). The Company’s synergistic collaboration with WHO-GMP manufacturing facilities is backed by an excellent rapport with clients.

Strong commitment of providing quality products is backed by in-depth industry knowledge, well-qualified team of professionals, as well as hi-tech and advanced infrastructure. Resulting in creating mutually beneficial associations for all the clients.

Adapting quickly to the ever-evolving demands, the Company has emerged as one of the fastest growing organization in the pharmaceutical industry in export of healthcare products from India. With headquarters located in the economic hub of India, Mumbai, our offices are also located in Kenya, & Vietnam. Further widening our reach overseas, the Company has entered into a joint venture with D.R., a Congo based company. The Company exports to countries like Africa, Kenya, Myanmar, Vietnam, Russia etc.

Adhering to high quality standards is not an accident but our habit. Passionate to be the best, we take pride in what we do and strive to deliver products with zero defects.

#### **Current COVID Situation:**

While the COVID 19 pandemic is rapidly evolving, Vaishali Pharma’s management continues to monitor the situation closely and take measures to maintain business continuity without compromising on the safety of its employees in any way.

We strictly follow the instructions given by the Central as well as the State Governments in this regard from time to time. Our employees have been permitted to work from home ever-since the announcement of lock down is made. All business reviews and discussions are conducted through video/audio conferencing facilities in order to ensure smooth running of operations as much as possible.

These are unprecedented times and we strongly believe that our asset light model will help us come out of this pandemic with a position of strength. Exposure to 25 and more countries with a wide range of portfolio covering from Generic medicines to consumables products proves to be beneficial and helps our business continuity over longer period of time.

**Management Comment:**

Commenting on the recent development, Mr. Atul Vasani, Managing Director, Vaishali Pharma Limited said:

“We are supporting our communities across the globe. All of our employees around the world have been strongly encouraged to work from home. We're also trying to make the most of the products available for our customers, partners and communities.

We sincerely hope that the current crisis resolves at the earliest and pray for the wellbeing of our stakeholders, manufacturers, distributors and other business partners”

For more details please visit: [www.vaishalipharma.com](http://www.vaishalipharma.com)

For any Investor Relations query, please contact:

**Mr. Atul Vasani**

**Managing Director**

**Vaishali Pharma Limited**

Email: [director@vaishalipharma.com](mailto:director@vaishalipharma.com)

**Note:** *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily*

*indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*